Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).

Abstract

BACKGROUND:

This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer.

PATIENTS AND METHODS:

Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-negative, stage II/III breast cancer received six cycles of 75 mg/m(2) docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN).

RESULTS:

Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery.

CONCLUSIONS:

Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.

• Authors: H R Kim, K H Jung, S-A Im, Y-H Im, S Y Kang, K H Park, S Lee, S-B Kim, K-H Lee, J S Ahn, S I Kim, J H Sohn
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 24 Issue 6 Pg. 1485-90 (Jun 2013) ISSN: 1569-8041 [Electronic] England
• PMID: 23380385 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Humanized
• Taxoids
• Docetaxel
• Bevacizumab
• Carboplatin

Topics

• Adult
• Aged
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Bevacizumab
• Breast Neoplasms (drug therapy, epidemiology, surgery)
• Carboplatin (administration & dosage)
• Docetaxel
• Female
• Humans
• Middle Aged
• Neoadjuvant Therapy (methods)
• Republic of Korea (epidemiology)
• Taxoids (administration & dosage)
• Treatment Outcome